Anna Navoikova

ORCID: 0000-0003-0224-1396
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • COVID-19 Clinical Research Studies
  • COVID-19 epidemiological studies
  • SARS-CoV-2 and COVID-19 Research
  • Influenza Virus Research Studies
  • CRISPR and Genetic Engineering
  • Virus-based gene therapy research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Respiratory viral infections research
  • Viral Infections and Vectors

Moscow Institute of Physics and Technology
2021-2024

During the ongoing coronavirus disease 2019 (COVID-19) pandemic, many individuals were infected with and have cleared virus, developing virus-specific antibodies effector/memory T cells. An important unanswered question is what levels of T-cell antibody responses are sufficient to protect from infection.

10.1093/cid/ciac278 article EN cc-by-nc-nd Clinical Infectious Diseases 2022-04-12

Influenza A viruses (IAVs) pose a serious threat to global health. On the one hand, these cause seasonal flu outbreaks in humans. other they are zoonotic infection that has potential pandemic. The most important natural reservoir of IAVs waterfowl. In this study, we investigated occurrence IAV birds Republic Buryatia (region Russia). 2020, total 3018 fecal samples were collected from wild migratory near Lake Baikal. Of samples, 11 found be positive for H13N8 subtype and whole-genome...

10.3390/v16040568 article EN cc-by Viruses 2024-04-07

Summary Rapid spread of COVID-19 pandemic made a substantial share the world population immunised by SARS-CoV-2 antigens. Infection induces development virus-specific antibodies and T cells. Ample evidence on antibody-mediated protection is contrasted elusive role cells in preventing infection. To explore impact to quantify protective levels immune responses we conducted large prospective study: 5,340 Moscow residents were evaluated for antibody cellular monitored up 300 days. The tightly...

10.1101/2021.08.19.21262278 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-08-22

INTRODUCTION . The creation of synthetic adeno-associated virus (AAV) vectors during gene therapy development is a labour-intensive and expensive process. optimal solution to minimise the time costs associated with lies in improvement methods aimed at assessing AAV vector biodistribution transduction efficiency vivo. AIM This study develop new bioinformatics-based assessment method for libraries analyse vivo MATERIALS AND METHODS production involved assigning serotype-specific barcodes...

10.30895/2221-996x-2024-24-2-215-228 article EN cc-by Biological Products Prevention Diagnosis Treatment 2024-06-14
Coming Soon ...